Modulation of Paraoxonase 1 Activity and Asymmetric Dimethylarginine by Immunomodulatory Therapies in Multiple Sclerosis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199728 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Lilla Racz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary. Hauptthemen laut MEDLINE: Aryldialkylphosphatase, Arginine, Multiple Sclerosis, Immunologic Factors. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neurodegeneration is present from the earliest stages of multiple sclerosis [MS], and oxidative stress together with mitochondrial dysfunction are key contributors to neuronal injury and disease progression.
Objective
To investigate the role of the antioxidant enzyme paraoxonase 1 (PON1) and serum asymmetric dimethylarginine (ADMA) levels in MS across different disease subtypes and immunomodulatory treatments.
Methods
Serum lipid levels and PON1 activity were measured and compared by disease subtype and treatment in a single-center MS cohort (N = 262; CIS = 10, RRMS = 208, PPMS = 19, SPMS = 25; 110 untreated, 152 treated) and in 91 healthy controls. ADMA levels were assessed in sera from 79 MS patients (19 untreated, 60 treated) and 31 age-matched controls.
Results
Median serum paraoxonase (PON) and arylesterase (ARE) activity levels were 83.8 and 127.2 IU/L in MS patients versus 85.9 and 136.9 IU/L in controls, with no significant difference for PON (p = 0.191) but a significant reduction in ARE [p = 0.003]. PON activity differed significantly among disease subtypes (p = 0.023), with the highest levels in CIS. PON and ARE activity also varied across treatment groups (p = 0.038 and p = 0.034, respectively), with longitudinal analysis indicating a measurable effect of immunomodulatory therapy on PON activity at 10 years (p = 0.0136). Significant differences in enzyme activity were observed between untreated and interferon-treated patients (PON p = 0.0055, ARE p = 0.0001), with trends toward differences in ARE under natalizumab and fingolimod. ADMA levels were lower in MS patients than controls (p < 0.0001) and differed among treatment subgroups (natalizumab, dimethyl fumarate, glatiramer acetate, untreated RRMS).
Conclusions
PON1 activity and ADMA levels differ between MS subgroups and under immunomodulatory treatments. Long-term therapy was associated with increased PON1 activity, while highly effective immunomodulators reduced ADMA levels. These changes may contribute to the treatment-related reduction in disease activity and attenuation of neurodegenerative processes in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
- Clinical Department of Infectious Diseases, University of Debrecen, 4032 Debrecen, Hungary.
ORCID-Profile: Lilla Racz, Hajnalka Lorincz, Laszlo Kardos, Tunde Csepany
Zitieren
APA
Racz, L., Lorincz, H., Seres, I., Kardos, L., Paragh, G., & Csepany, T. (2025). Modulation of Paraoxonase 1 Activity and Asymmetric Dimethylarginine by Immunomodulatory Therapies in Multiple Sclerosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199728
Vancouver
Racz L, Lorincz H, Seres I, Kardos L, Paragh G, Csepany T. Modulation of Paraoxonase 1 Activity and Asymmetric Dimethylarginine by Immunomodulatory Therapies in Multiple Sclerosis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199728
BibTeX
@article{Racz2025,
author = {Racz, Lilla and Lorincz, Hajnalka and Seres, Ildiko and Kardos, Laszlo and Paragh, Gyorgy and Csepany, Tunde},
title = {Modulation of Paraoxonase 1 Activity and Asymmetric Dimethylarginine by Immunomodulatory Therapies in Multiple Sclerosis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199728}
}
EUVIMED